Timothy A. Springer

Overview

Timothy A. Springer is a private investor specializing in biotechnology and healthcare sectors. He has been instrumental in founding and funding several biotech companies, particularly in immunology and cell biology. His investment approach focuses on identifying and supporting innovative companies that have the potential to make significant impacts in the medical field. Springer has a history of early investments in companies like Moderna, where his $5 million investment in 2010 led to substantial returns following the company's IPO in 2018. He also co-founded Morphic Therapeutic in 2015, a company focused on integrin-targeted medicines, which was acquired by Eli Lilly in 2024 for approximately $3.2 billion. Additionally, Springer has been involved in the founding of Scholar Rock in 2012, Tectonic Therapeutic in 2019, and Seismic Therapeutic in 2022, all of which are focused on advancing treatments in immunology and related fields. His investment philosophy centers on supporting companies that are at the forefront of medical innovation, particularly those developing therapies for complex diseases. Through his strategic investments, Springer has contributed to the growth and success of multiple biotech firms, demonstrating a commitment to advancing healthcare through innovation. His active involvement in these companies reflects a hands-on approach to fostering growth and achieving impactful outcomes in the biotech industry.

Investment Focus

• Innovative biotech companies with strong growth potential
• Focus on immunology and cell biology sectors
• Companies at various stages from seed to pre-IPO

Portfolio Companies